Background and aim: Many neuroendocrine gastrointestinal tumours express receptors for the regulatory peptide somatostatin. Among the five existing somatostatin receptor (sst) subtypes, sst2A is the most frequently expressed in these tumours. However, little information is available about the cellular location of sst2A in corresponding non-neoplastic epithelial tissues. Methods: We searched for sst2A immunoreactive cells in non-neoplastic gastrointestinal tissues, and evaluated their number and immunohistochemical characteristics with neuroendocrine markers. Results: The gastric antrum showed numerous sst2A cells, situated in the epithelium, corresponding to gastrin containing neuroendocrine cells, while the gastric corpus was largely devoid of sst2A cells, including enterochromaffin-like cells. The remaining foregut, namely the duodenum and proximal jejunum, also contained a large number of sst2A cells, all being neuroendocrine cells and many of them characterised as gastrin cells. Sst2A cells were also detected in the midgut, in low numbers in the epithelium of the distal jejunum and ileum, but not in the appendix vermiformis, the caecum, or the hindgut, despite the large number of neuroendocrine cells present in this area. In addition, sst2A cells were found in the whole gastrointestinal tract in the myenteric and submucosal plexus. Conclusions: While sst2A receptors on antral gastrin cells presumably mediate somatostatin inhibition of gastrin secretion, the effects of somatostatin on motility and ion transport in the lower gastrointestinal tract may be mediated by sst2A receptors in the neural plexus. These data provide a molecular basis for the physiological actions of somatostatin in human gastrointestinal tissue.
S
omatostatin receptors (sst) are frequently expressed in neuroendocrine tumours of the gut 1 2 and hence provide the basis for in vivo targeting of these tumours with somatostatin analogues. [3] [4] [5] For instance, the beneficial effect of octreotide therapy, a stable analogue of somatostatin, on hormonal secretion in somatostatin receptor expressing neuroendocrine tumours of the gut 3 is well documented. Furthermore, [ 111 In-DTPA 0 ]-octreotide has been successfully used to detect these tumours by receptor scintigraphy in vivo. 4 Moreover, radiotherapy with 90 Y-DOTATOC has been performed in clinical phase I studies showing remission or stabilisation of disease in the majority of patients with end stage cancer. 4 Compared with cancer, information on the cellular localisation of the sst protein in non-neoplastic human gut tissues is limited. In vitro receptor autoradiography detected sst in the non-neoplastic gut mucosa as well as in lymphoid tissue, nerve plexus, circular smooth muscle at the mucosa directed margin, and the vasculature 2 6-8 but without precise cellular localisation and without receptor subtype specification. In situ mRNA hybridisation and reverse transcriptionpolymerase chain reaction in non-neoplastic colon tissue detected all subtypes, most often sst2 or sst5, localised in the epithelium as well as in the lamina propria. 9 10 In the present study, we took advantage of a very well characterised sst antibody, R2-88, 11 that identifies one of the most abundant sst subtypes in neuroendocrine tumours, namely the splice variant sst2A. 12 Immunohistochemistry can be done on formalin fixed tissue, the most often available tissue fixation, and single cells are detectable. Hence we have evaluated the presence of sst2A protein in non-neoplastic formalin fixed tissue of various parts of the human gut. We compared the results with neuroendocrine markers on serial sections. In the gastric antrum, sst receptor autoradiographic results on frozen tissue were correlated with those of sst2A immunohistochemistry. Knowledge of the distribution of sst2 in normal human tissues provides new insights into the physiology of somatostatin. It may also be of value in understanding the carcinogenesis of sst2 positive neuroendocrine tumours.
MATERIAL AND METHODS

Tissues
Formalin fixed paraffin embedded tissue samples from resection specimens collected at the Institute of Pathology were selected, showing non-neoplastic tissue with a normal histology on sections cut perpendicular to the mucosal surface. Tissue samples were collected per anatomical location (table 1) . 125 I-LTT-SS-28. After sections were washed, they were apposed to BiomaxMR films (Kodak, Lausanne, Switzerland) and exposed for one week in x ray cassettes. Non-specific binding was determined in parallel sections incubated with the same concentration of labelled peptide in the presence of 10 26 mol/l of unlabeled octreotide or SS-28, respectively.
Receptor autoradiography
Immunohistochemistry
We used the polyclonal rabbit antibody R2-88 raised against a unique sequence in the carboxyl terminal region of the sst2A receptor, corresponding to amino acids 339-359 in the rat protein. The identical sequence is found in human, rat, and mouse sst2A receptor proteins, and as a result the antibody was shown to be highly specific on human tissue, both fresh frozen and formalin fixed paraffin embedded samples. 12 Formalin fixed paraffin embedded sections, cut at 223 mm, were dewaxed, rehydrated, and boiled in 100 mM Tris with 5% urea, pH 9.5, in a pressure cooker for five minutes. After pretreatment (and following all subsequent steps), sections were washed in Tris buffered saline (TBS). Sections were incubated overnight at room temperature with the sst2A antibody diluted 1:2000 in TBS containing 1% bovine serum albumin, 5% normal goat serum, and 0.1% NaN 3 . Sections were then incubated with a biotinylated goat-antirabbit antibody (1:200; same buffer as for the primary antibody; DakoCytomation, Glostrup, Denmark) and thereafter with avidin-biotin complex/horseradish peroxidase (DakoCytomation; 1:120 in TBS). Finally, sst2A stained sections were developed in 0.05% 3,39-diaminobenzidine and H 2 O 2 , weakly counterstained with haematoxylin, and mounted. For all cases, an additional adjacent tissue section was incubated with the primary sst2A antibody that had been preabsorbed with an excess (100 nM) of the peptide antigen prior to staining, to serve as a specificity control.
In addition, we performed immunohistochemical staining on serial sections with the following commercially available rabbit polyclonal antibodies: gastrin (1:300), chromograninA (CgA; 1:300), protein S100 (1:800, as a marker of peripheral nerve cells) (all from DakoCytomation), and histidine decarboxylase (HDC; 1:2000; Progen, Heidelberg, Germany). After dewaxing and rehydrating, sections were boiled in 10 mM citrate buffer, pH 6.0, for five minutes (CgA, gastrin) or 10 minutes (HDC) in a pressure cooker. After pretreatment, sections were incubated for 60 minutes at room temperature with CgA, protein S100, HDC, or gastrin diluted in TBS containing 0.5% casein sodium salt and 5% goat serum. Subsequently, sections were incubated with biotinylated secondary antibody (1:500) and thereafter with streptavidin-biotin complex/alkaline phosphatase (1:200 in TBS) (both DakoCytomation). Sections were developed with new fuchsin-naphtol AS-BI, weakly counterstained with haematoxylin, and mounted.
In selected specimens from the antrum, we performed immunofluorescence double staining on formalin fixed paraffin embedded sections. The primary antibodies included the above polyclonal rabbit antibody sst2A and a monoclonal mouse-antihuman CgA antibody (Clone DAK-A3; DakoCytomation). Sections were cut at 223 mm, dewaxed, rehydrated, and boiled in 100 mM Tris with 5% urea, pH 9.5, in a microwave oven. Sections were incubated overnight at room temperature with CgA diluted 1:100 and sst2A diluted 1:1000 in TBS containing 0.5% casein sodium salt and 5% goat serum. Red (Alexa Fluor 546) and green (Alexa Fluor 488) fluorochrome labelled secondary antibodies (Molecular Probes, Eugene, Oregon, USA) were used to visualise target structures. Goat-antirabbit Ig antibodies were used at 1:600 and goat-antimouse Ig at 1:300, and were incubated for 45 minutes.
Estimation of receptor positive cells/cm mucosa
Tissue samples were photographed at low magnification (1.256 objective, eyepiece 106). The length of the lamina muscularis was then measured on photographed sections that were cut perpendicular to the mucosal surface. On serial sections, the number of immunohistochemically positive cells was counted in the epithelium, at a medium magnification (106 objective, eyepiece 106), permitting visualisation of the entire mucosal height in the visual field. For various investigated anatomical locations, tissue samples contained a total mucosal length of a minimum of 3.3 cm (corpus) and up to a maximum of 7.2 cm mucosa (colon). Median (SD) count/cm mucosa in each anatomical location was calculated. Count/cm mucosa could then be compared with published counts/cm 2 based on a section thickness of 2 mm.
RESULTS
Sst2A receptor proteins were expressed immunohistochemically at several locations in the non-neoplastic gut (table 2) . In the upper gut, sst2A cells were most numerous (table 2) in the mucosa of the gastric antrum, situated in the 1B) . Displacement of the ligand with unlabelled sst2, sst3, and sst5 selective analogues revealed the predominance of subtype 2 ( fig 1B) . At high power magnification, sst2A were exquisitely membrane bound in basket shaped cells located at the basement membrane in the mucosal foveolae (fig 2) . On serial sections, these cells all belonged to a larger population of CgA cells in this area. In addition, they were always positive for gastrin located in the cytoplasm (figs 1, 2) .
Results of serial sections were further confirmed by double immunofluorescence staining with a combination of sst2A and CgA, revealing individual double positive cells in the foveolae at the neck of the glands, basket or oval shaped, and basement membrane based, as described above, with membrane bound sst2A and cytoplasmic CgA (fig 2) . We detected no sst2A cells in the epithelium of the gastric corpus. On the one hand, we identified in this location all neuroendocrine cells, as measured by CgA immunohistochemistry. On the other hand, we detected enterochromaffinlike (ECL) cells by immunostaining of specific HDC. Theses ECL cells were present in the lower part of the corpus. Even when focusing on these ECL cells in serial sections, no sst2A were detected. In agreement with this, we did not detect sst2 in the mucosa of the corpus on receptor autoradiography. Interestingly, in samples containing both normal mucosa as well as hyperplastic ECL cell lesions and/or ECL cell tumours, only hyperplasia and tumours expressed large amounts of membrane bound sst2A (see below).
The duodenum and proximal jejunum also contained epithelial sst2A cells while only rare sst2A cells were detected in the distal jejunum and ileum (table 2). Figure 3 shows a In the appendix vermiformis, colon and rectum, no sst2A cells were detected in the epithelium, despite large number of detected neuroendocrine CgA positive cells (table 2) . Conversely, in the submucosa and tunica muscularis, ganglionic cells were strikingly sst2A positive (fig 4) and identified on serial sections as neural cells by their positivity for the peripheral nerve cell marker protein S100. We found sst2A cells in the myenteric and submucosal plexus in the whole gastrointestinal tract, including the stomach, duodenum, jejunum, ileum, appendix vermiformis, colon, and rectum.
It should be noted that the number of cells/cm mucosa detected by CgA and gastrin immunohistochemistry in the present study were in the range of previous investigations. 13 14 For comparison, fig 5 shows the extent of sst2A positivity in various gut neuroendocrine lesions, using identical immunohistochemical methodology: ECL cell hyperplasia as well as an ECL cell tumour of the stomach, gastrinoma of the duodenum, and an ileal carcinoid, all strongly expressing sst2A at the membrane of hyperplastic or neoplastic cells.
DISCUSSION
This is the first description of immunohistochemically detected sst2A protein at the cellular level in the epithelium of non-neoplastic human gut. There were large differences in the amounts of sst2A cells in different areas of the gut. Sst2A cells correspond to defined cell populations but they do not necessarily parallel the neuroendocrine cell population. In gut epithelium, sst2A positive cells are neuroendocrine cells. In the gastric antrum, sst2A cells represent mostly neuroendocrine gastrin cells whereas in the lower gut neuroendocrine epithelial cells do not express sst2A. However, sst2A receptors are clearly expressed in the submucosal and myenteric plexus throughout the whole of the gastrointestinal tract, a finding that extends our previous immunohistochemical observation of sst2A cells in the neural plexus of the human colon. 7 The sst2A antibody R2-88 has previously been well characterised and shown to be highly specific for the sst2A receptor 11 in animal and human tissues and to correlate well with other methodologies such as in vitro sst autoradiography or mRNA in situ hybridisation. 12 The present study further emphasises the excellent characteristics of the antibody by showing: good correlation between in vitro receptor autoradiography and immunohistochemistry in the gastric antrum where sst2A cells were dense and numerous enough to generate an autoradiographic signal; consistent results in the normal part of surgical samples of patients with different malignant neoplasms and different inflammatory lesions; and unambiguous characterisation of sst2A cells by other immunohistochemical markers.
Detection of sst2A cells in the epithelium in the foregut and in the neural plexus throughout the gastrointestinal tract adds to our understanding of the cellular mechanisms involved in the physiological actions of somatostatin in humans. Although substantial information is available regarding the action of somatostatin in the gastrointestinal tract in mice and rats, 15221 direct investigation using human tissues is necessary to extrapolate from animals to humans as species differences are widely observed with peptides and peptide receptors. 5 In the human foregut (stomach to proximal jejunum), the sst2A receptor protein on antral gastrin cells is likely to represent the molecular basis for the inhibitory effect of somatostatin on gastrin secretion, 22 mediated in a paracrine way through cytoplasmic processes of somatostatin cells projecting onto gastrin cells. 23 In the rodent, there is as yet no evidence for sst2A expression in antral gastrin cells. 21 Conversely, there is good evidence in the rodent for a multiple somatostatin action on parietal cells and ECL cells through sst2A receptors 17 20 21 (Reubi unpublished data) whereas our present human data do not suggest a somatostatin action through sst2A in cells of the corpus. An action of somatostatin in the corpus of the human stomach may however be mediated by sst1, as suggested recently by in vitro receptor autoradiographic data. 2 The present human data clearly favour a predominant role of somatostatin through sst2A at the level of gastrin cells: the high number of sst2A expressing gastrin cells and the consistency of the labelling throughout the different tissue samples may underline the importance of this mechanism in human tissue. The present data therefore clearly indicate a species difference in the location of sst2A receptors in the stomach between humans and rodents. In the duodenum and proximal jejunum, sst2A cells were found to always represent neuroendocrine cells, subtyped most often as gastrin cells. In the midgut (distal jejunum to caecum) and hindgut (colon and rectum), where rare and no sst2A cells, respectively, were found in the epithelium, the action of somatostatin may be primarily mediated by sst2A receptors on neural cells in the plexus submucosus and myentericus. These receptors, found throughout the neural plexus of the gastrointestinal tract, may represent the molecular basis for sst2 mediated inhibition of gut motility by somatostatin. 24226 Those in the plexus submucosus may also represent the molecular basis for somatostatin inhibition of colonic ion secretion, as shown in a human in vitro model 27 of colonic tissue samples stripped of underlining connective tissue. The submucosal plexus is the only location in the mucosa and submucosa of the colon where we detected sst2A cells. In the rodent, sst2A positive cells are also found in this location. 20 Can the present study add to our understanding of the carcinogenesis of gut neuroendocrine tumours? While specific areas of the human gut have a large number of sst2A receptor containing cells, our data show that other areas, such as the gastric corpus as well as the mid and hindgut, have no or surprisingly few sst2 expressing cells in nonneoplastic epithelium. Interestingly, mid and hindgut are regions where the majority of gut neuroendocrine tumours 28 arise, and these are characterised by high sst2 receptor expression. On the basis of the sst2 expressing cells identified in the mid and hindgut in the present study, it is therefore difficult to define the cell of origin of mid and hindgut neuroendocrine tumours. 14 29234 In the gastric corpus however, from which neuroendocrine tumours arise that are predominantly ECL cell tumours with high sst2 expression, 35 one may speculate that the absence of sst2A in normal ECL cells (even in those patients with sst2A positive tumours) indicates that ECL cell tumours and preinvasive hyperplastic lesions may express sst2 de novo. 
